Introduction
The formation of new blood vessels promoting tumor growth is termed angiogenesis and is controlled by the production and release of soluble factors, one of which is vascular endothelial growth factor (VEGF) (Hanahan and Weinberg, 2000; Ferrara et al., 2003) . Oncogenes such as Ras and B-Raf (Kranenburg et al., 2004) are potent stimulators of VEGF expression. Whereas, the identification of pro-and antiangiogenic factors enabling tumor cells to elicit endothelial cell responses has been intensively studied, less is known about integrin signals regulating tumor growth (Boudreau and Myers, 2003; Guo and Giancotti, 2004) . Antibody-mediated blockage (Weaver et al., 1997) , dominant-negative inhibition , or genetic inactivation (White et al., 2004) of integrins prevents tumor progression. As integrin-linked kinase can promote tumor growth (Tan et al., 2004) and b1-integrin expression is critical for mammary tumorigenesis in vivo (White et al., 2004) , it is important to determine the linkage of a b1-integrin-activated protein-tyrosine kinase (PTK) such as focal adhesion kinase (FAK) to tumor progression.
Focal adhesion kinase is localized to sites of integrin clustering where it functions as an important regulator of cell motility and can affect the activation of various downstream signaling pathways (Hanks et al., 2003; Parsons, 2003; . Integrin-stimulated FAK phosphorylation at Y397 promotes the Src homology domain 2 (SH2)-dependent binding of Srcfamily PTKs and the formation of an activated FAKSrc complex. Src-mediated phosphorylation of FAK at Y576/Y577 enhances FAK catalytic activity and Src phosphorylation of FAK at Y925 promotes Grb2 SH2-mediated binding Mitra et al., 2005) . However, Y925 FAK phosphorylation and Grb2 binding to FAK remain unproven as a bona fide linkage promoting mitogen-activated protein kinase (MAPK) activation (Schlaepfer and Hunter, 1997; Schlaepfer et al., 1998; Barberis et al., 2000; SlackDavis et al., 2003) . Moreover, a role for intrinsic FAK activity or Y925 FAK tyrosine phosphorylation in tumorigenesis remain unknown.
Overexpression of the FAK C-terminal domain (FRNK) inhibits FAK activity and dominant-negative FRNK can be inactivated by a point mutation (FRNK S-1034) that disrupts FRNK colocalization with integrins (Sieg et al., 1999) . Whereas, high levels of FRNK can promote cell apoptosis (Xu et al., 2000; Golubovskaya et al., 2002) , lower expression levels of FRNK in tumor cells have revealed the importance of FAK activity in promoting migration (Slack et al., 2001) and in generating an invasive phenotype van Nimwegen et al., 2005) .
Despite correlations between elevated FAK expression and an aggressive tumor phenotype (GabarraNiecko et al., 2003; Hecker and Gladson, 2003) , there is limited information on how FAK signaling contributes to tumor progression in situ (McLean et al., 2005) . This is because observed alterations in tumor growth by FAK (Wang et al., 2000) or FRNK (Aguirre Ghiso, 2002) overexpression have also been linked to changes in tumor cell proliferation in vitro (Ding et al., 2005; van Nimwegen et al., 2005) . Although targeted deletion of fak suppressed chemically induced skin tumor formation in mice (McLean et al., 2004) , elevated apoptosis was observed in both normal and tumor cells after fak deletion (McLean et al., 2004; Shen et al., 2005) . Thus, FAK-mediated regulation of cell survival complicates interpretations of FAK function in vivo.
Here, we inhibited FAK activity via stable FRNK expression in 4T1 breast carcinoma cells and found that this was not associated with alterations in cell proliferation or anchorage-independent cell survival in vitro. However, FRNK-expressing 4T1 cells secreted less VEGF and formed small avascular tumors without exhibiting differences in tumor-associated apoptosis compared to controls. We found that FRNK inhibited a FAK-Grb2-MAPK-signaling linkage regulating VEGF expression. The biological importance of this FAK-signaling pathway was confirmed through reconstitution experiments using Src-transformed FAK-null fibroblasts where point-mutations affecting FAK catalytic activity or Y925 phosphorylation disrupted the ability of FAK to promote MAPK-and VEGFassociated tumor growth. Inhibition of FAK expression in breast, prostate and neuroblastoma cells also resulted in reduced VEGF expression. As our results are the first to show that intrinsic FAK catalytic activity promotes tumor progression and that Y925 FAK phosphorylation acts as a bona fide signaling pathway to MAPK regulating VEGF expression, our studies strongly support the development of inhibitors to FAK as antitumor agents.
Results

FRNK inhibits breast carcinoma cell growth as tumors
Focal adhesion kinase expression is elevated in latestage breast carcinoma tumor samples (Cance et al., 2000; Lark et al., 2005) . However, histological analyses of tumors show that changes in FAK expression occur prior to the acquisition of an aggressive phenotype (Lightfoot et al., 2004) . To evaluate whether differences in FAK expression correlate with alterations in tumor growth, various human (MCF-7, MDA-MB-468, MDA-MB-435, MDA-MB-231) and murine (4T1) breast carcinoma cells were analysed in chicken chorioallantoic membrane (CAM) tumor growth assays.
Notably, FAK expression and FAK Y397 tyrosine phosphorylation were highest in MDA-MB-231 and 4T1 cells that formed large tumors with high levels of neo-vascularization ( Figure 1a) .
4T1 carcinoma cells are derived from a spontaneously arising BALB/c mouse mammary tumor (Heppner et al., 2000) . To test the importance of FAK activity in 4T1 growth, green fluorescent protein (GFP)-tagged FRNK was expressed as a dominant-negative inhibitor of FAK activity. A point mutant of GFP-FRNK (Leu-1034 to Ser, S1034) that does not colocalize with integrins or GFP were used as controls (Figure 1b) . In stable pooled populations of cells, GFP-FRNK and GFP-FRNK S1034 were expressed at B2-fold higher levels than endogenous FAK (Figure 1c , and data not shown). Although FRNK expression did not alter the pattern of tyrosine-phosphorylated proteins in 4T1 cells (Figure 1c ), FAK in vitro kinase (IVK) analyses revealed B50% reduction in FAK autophosphorylation levels in 4T1-FRNK compared to 4T1-GFP and 4T1-FRNK S1034 cells (Figure 1d) .
No difference in 4T1-FRNK cell proliferation compared to controls was observed under either anchorage-dependent (Figure 1e ) or anchorage-independent conditions (Figure 1f ). Further, FRNK and FRNK S1034-expressing 4T1 cells exhibited equal levels of apoptosis when held in suspension for 72 h (Figure 1g) . Surprisingly, when analysed for growth as subcutaneous tumors in mice, 4T1-FRNK cells formed threefold smaller tumors compared to 4T1-FRNK S1034 cells which formed tumors equal in size to 4T1 controls ( Figure 2a ). No differences in apoptosis between 4T1-FRNK, 4T1-FRNK S1034 and 4T1-GFP cells were found by terminal deoxy transferase uridine triphosphate nick end labeling (TUNEL) ( Table 1) or activated caspase-3 (data not shown) staining of tumor sections. However, visual analyses of 4T1 control and FRNK S1034 tumors revealed blood vessel accumulation on the tumor surface whereas the smaller 4T1-FRNK tumors did not exhibit this phenotype (data not shown).
4T1-FRNK tumors exhibit an avascular phenotype
To determine whether FRNK expression was inhibiting the production of an angiogenic factor, reverse transcriptase-polymerase chain reaction (RT-PCR) analyses were performed on RNA isolated from medial tumor tissue samples. two-to threefold increased murine VEGF-120 and VEGF-164 levels were observed in 4T1-FRNK S1034 tumors compared to 4T1-FRNK tumors with equal co-amplification of an internal b-actin control (Figure 2b ). By immunoblotting, equal levels of FRNK or FRNK S1034 were expressed in the tumors (Figure 2b ). The small 4T1-FRNK tumors were compact and avascular compared to 4T1-FRNK S1034 tumors as determined by hematoxylin and eosin staining and immuno-detection of an endothelial cell marker, Tie-2 (Figure 2c ). Evaluation of tumor sections showed B30-fold difference in blood vessels present in the periphery of 4T1-FRNK S1034 compared to the avascular 4T1-FRNK tumors (Figure 2d ). Differences in tumor growth and vascular recruitment were also apparent when 4T1 control, 4T1-FRNK and 4T1-FRNK S1034 cells were grown on chicken CAMs for 7 days (Figure 2e and f) . To determine the role of neo-vascularization in 4T1 tumor growth, functionblocking antibodies to integrins avb3 (LM609) or to avb5 (P1F6) were injected into the chicken venous circulatory system 3 days after 4T1 cell implantation on CAMs when a tumor mass became visible. These antibodies react with chicken but not mouse integrins and thus do not directly target the 4T1 tumor cells. As angiogenic factors such as VEGF and basic fibroblast growth factor (bFGF) function through co-dependent interactions with endothelial cell-associated integrins (Friedlander et al., 1995; Hood et al., 2003) , injection of anti-integrin antibodies can provide evidence of the importance of a particular angiogenic pathway in promoting tumor growth. In a 4-day experimental window, P1F6 injection resulted in B30% reduction in tumor size compared to LM609 antibody or phosphate-buffered saline (PBS) control groups ( Figure 2g ). As LM609 inhibits the growth of other tumor cells on CAMs (data not shown), the P1F6 results support the importance of a VEGF-avb5 signaling axis for 4T1 tumor growth.
FRNK inhibits 4T1 breast carcinoma VEGF production To determine whether FRNK expression inhibits VEGF production of 4T1 cells in culture, conditioned media (cells grown in Dulbecco's-modified Eagle's medium (DMEM) with 0.5% fetal bovine serum (FBS)) was analysed by anti-VEGF enzyme-linked immunosorbent assay (ELISA). FRNK inhibited VEGF secretion B2-fold compared to FRNK S1034 and GFP control 4T1 cells ( Figure 3a ) and VEGF production differences were verified by blotting the heparin-sepharose bound fraction of 4T1 cell-conditioned media (Figure 3b ). To evaluate whether increased VEGF expression was sufficient to account for differences in tumor growth, recombinant VEGF was added to 4T1-FRNK cells after implantation on CAMs. VEGF addition promoted a B7-fold increase in tumor mass compared to untreated 4T1-FRNK cells (Figure 3c ). VEGF-treated 4T1-FRNK cells also formed 2.5-fold larger tumors than 4T1-FRNK S1034 controls. As 4T1 cells express Flt-1 and neuropilin-1 but not Flk-1 as VEGF receptors (Barr et al., 2005) , and 100 ng/ml epidermal growth factor but not equivalent addition of VEGF-stimulated 4T1 cell proliferation in culture (data not shown), the resultant increased tumor growth upon VEGF addition to the CAM supports the importance of angiogenesis and not autocrine effects on 4T1 growth as tumors.
To determine whether reduced VEGF expression from 4T1-FRNK cells is biologically significant, conditioned media was evaluated for effects on human umbilical vein endothelial cell (HUVEC) proliferation. HUVECs were starved in minimal (Min.) media containing 0.2% FBS for 24 h and then analysed for bromodeoxyuridine (BrdU) incorporation upon addition of either endothelial growth media (EGM), DMEM (containing 3.3% FBS), or conditioned media from 4T1-FRNK or 4T1-FRNK S1034 cells. 4T1-FRNK S1034-conditioned media stimulated HUVEC proliferation by 25% above EGM and DMEM controls ( Figure  3d and e), a response identical to 4T1-GFP controlconditioned media (data not shown). Similar levels of increased HUVEC proliferation were observed upon recombinant VEGF addition, and BrdU incorporation stimulated by 4T1-FRNK S1034-conditioned media was blocked in the presence of a VEGF receptor (SU5416) inhibitor ( Figure 3d ). In contrast, 4T1 FRNK-conditioned media did not promote HUVEC proliferation ( Figure 3d ). Together, these results support the conclusion FRNK-mediated inhibition of FAK activity blocks a signaling pathway regulating VEGF expression and angiogenesis.
Site-specific inhibition of focal adhesion kinase phosphorylation and extracellular signal-regulated kinasemitogen-activated protein kinase activation by FRNK Studies to date show that FAK functions as both a signaling kinase and scaffolding protein (McLean et al., 2005) . To determine how FRNK inhibited FAKassociated signaling, FAK was immunoprecipitated (IP) from 4T1-FRNK or 4T1-FRNK S1034 cells ( Figure 4a) . Surprisingly, anti-phosphotyrosine (pY) blotting of FAK IPs revealed only slight reduction in overall FAK pY content in 4T1-FRNK cell lysates. However, using various site-and phospho-specific anti-FAK antibodies to re-probe FAK IPs, FAK tyrosine (Y) phosphorylation at residues Y576, Y577, Y861 and Y925 was specifically reduced in 4T1-FRNK lysates ( Figure 4a ). Y397 FAK remained highly phosphorylated in the presence of FRNK and this likely contributes to overall pY content of FAK in 4T1-FRNK cells. The loss of Y576 and Y577 phosphorylation within the FAK kinase domain activation loop is consistent with FRNK-mediated inhibition of FAK activity ( Figure 1d ). The reduction in FAK Y861 and Y925 phosphorylation have been previously shown to disrupt b5-integrin association and SH2-mediated Grb2 adaptor protein binding, respectively (Schlaepfer et al., 1994; Eliceiri et al., 2002) . FRNK was not detectably phosphorylated on tyrosine.
To test the significance of decreased pY925 phosphorylation and to determine whether FAK forms a signaling complex with Grb2 in 4T1 cells, co-IP analyses were performed. A Grb2-FAK complex in lysates of 4T1-FRNK S1034 cells was detected at B5% of total FAK levels and this Grb2 association with FAK was inhibited in 4T1-FRNK lysates ( Figure 4b ). As Grb2 binding to FAK is a possible link to extracellular signal-regulated kinase (ERK)2/MAP kinase activation, phospho-specific antibodies were used to evaluate mitogen-activated protein kinase kinase 1 (MEK1) and ERK2 activation in lysates of 4T1-FRNK and 4T1-FRNK S1034 cells. MEK1 IPs showed B50% reduction in serine (S) phosphorylation at S217 and S221 in FRNK-expressing cells whereas no difference in MEK1 phosphorylation at S298 was observed (Figure 4c ). Phospho-specific blotting and IVK assays revealed B50% inhibition of ERK2 activity in 4T1-FRNK compared to 4T1-FRNK S1034 cells (Figure 4d ). These results are consistent with the loss of signaling through a FAK-Grb2-RasRaf-MEK1-ERK2 pathway upon FRNK expression in 4T1 cells.
As treatment of 4T1 cells with inhibitors to MEK1 (UO126 or PD98059) resulted in the inhibition of VEGF expression (data not shown), the importance of ERK2 activation in promoting VEGF expression was tested by using recombinant adenovirus (Ad) to overexpress constitutively activated (CA) MEK1 in 4T1-FRNK cells (Figure 4e ). Compared to mock-infected cells, CA-MEK1 promoted increased expression of all three murine VEGF isoforms (VEGF-120, -164 and -188) as determined by blotting ( Figure 4e ) and RT-PCR analyses (data not shown). These differences were confirmed by ELISA whereby CA-MEK1 expression in 4T1-FRNK cells promoted a twofold increase in VEGF expression, to 80% of the level produced by 4T1-FRNK S1034 cells (Figure 4f) . Notably, CA-MEK1 expression rescued 4T1-FRNK tumor growth on CAMs (Figure 4f ) and the change in VEGF induced by CA-MEK1 correlates with the ability of recombinant VEGF to promote 4T1-FRNK tumor growth (Figure 3c ). Finally, CA-MEK1 expression had only minimal effects on 4T1-FRNK S1034 VEGF expression and tumor growth on CAMs (Figure 4f ) as ERK2 is highly activated in 4T1-FRNK S1034 cells and CA-MEK1 did not significantly enhance ERK2 activity in these cells (data not shown). Together, these results point to the importance of FAK catalytic activity and a signaling linkage to ERK2/MAP kinase in promoting 4T1 VEGF expression and tumor growth.
Viral Src-transformed focal adhesion kinase-null fibroblasts exhibit an avascular tumor phenotype As most tumor cells express FAK, and in order to test the signaling role of FAK in a null model cell system, comparisons were made between viral Src (v-Src)-transformed FAK-null (FAKÀ/À) and FAK-reconstituted (clone DA2) fibroblasts. Previous studies showed that v-Src could rescue FAK-null cell motility defects, however, the role of FAK in activated Src-stimulated tumor growth remains undefined (Hsia et al., 2003; Moissoglu and Gelman, 2003) . In cell culture, FAKÀ/À v-Src and DA2 v-Src cells proliferate equally in low serum ( Figure 5a ) and in soft agar (Figure 5b ). When injected subcutaneously into nude mice, FAKÀ/À and DA2 v-Src fibroblasts exhibit equal tumor nodule formation up to 8 days (Figure 5c ). At this point, DA2 v-Src tumors began to grow at an enhanced rate. By day 14, DA2 v-Src tumors were B3-fold larger than FAKÀ/À v-Src tumors (Figure 5c ).
Staining of FAKÀ/À v-Src tumors revealed that they were composed of a dense and avascular tumor cell mass whereas DA2 v-Src tumors contained large sinusoids lined with Tie-2-positive endothelial cells (Figure 5d ). The vascular phenotype of DA2 v-Src tumors was associated with elevated levels of VEGF expression as determined by tumor staining (Figure 5d ) and RT-PCR analyses (Figure 5e ). Injection of fluorescein isothiocyanate (FITC)-lectin into the mouse circulation to label endothelial cells showed that DA2 v-Src tumors contained >8-fold more blood vessels in contact with the mouse circulation than FAKÀ/À v-Src tumors ( Figure 5f ). As no differences were observed when staining for markers of tumor cell proliferation or apoptosis (data not shown), and as activated Src is a potent activator of VEGF expression (Jiang et al., 1997), phosphorylation as detected by phospho-specific blotting to the MEK1/2 phosphorylation sites (pT185/pY187) followed by ERK2 blotting. In vitro kinase (IVK) activity was quantifed by a phosphorimager and presented as arbitrary units (a.u.). Bars are means 7s.e. of three independent experiments (n ¼ 4). (e) 4T1-FRNK cells were untreated (Mock) or infected with adenoviruses (Ad)-expressing constitutively activated (CA) MEK1. After 48 h, protein lysates were blotted for VEGF, MEK1 and b-actin. Indicated are the VEGF-120, -164, -188 and -120 (dimer, D) isoforms. (f) VEGF enzyme-linked immunosorbent assay (ELISA) with conditioned media (black bars) or chorioallantoic membrane (CAM) tumor growth assays (white bars) were performed using the indicated cells with or without Ad CA-MEK1 pre-infection for 48 h. Values are percentages 7s.e. plotted against FRNK S1034 mean value set to 100.
these results support the conclusion that FAK regulates the angiogenic switch downstream of Src. ( Figure 6b ). All GFP-FAK constructs were highly phosphorylated at Y397 (Figure 6b ). Wild-type and F925 FAK strongly localized to focal contact sites in FAKÀ/À v-Src cells whereas GFP was cytoplasmically distributed (Figure 6c ). R454 FAK also localized to focal contacts, however, FAKÀ/À v-Src cells expressing this mutant exhibited decreased spreading on fibronectin (Figure 6c ). This was not due to the absence of R454 FAK tyrosine phosphorylation (Figure 6b and d) , but is likely due to the lack of R454 FAK intrinsic catalytic activity (Figure 6d ).
Previous comparisons of FAKÀ/À v-Src and DA2 v-Src cells showed that FAK enhanced serum-stimulated ERK2 activation (Hsia et al., 2003) . In WT FAK reconstituted cells, ERK2 activity was B2-fold higher compared to control GFP-expressing cells (Figure 6e ). ERK2 activity was not significantly different in F925 FAK cells compared to GFP control cells whereas there was a slight decrease in ERK2 activity in R454 FAK cells (Figure 6e ). These ERK2 activation differences were not associated with differences in growth in culture (Figure 6f ) or in soft agar (data not shown). However, when grown as subcutaneous tumors in nude mice, WT FAK-reconstituted cells formed significantly larger tumors (P ¼ 0.001) compared to control FAKÀ/À v-Src cells (Figure 6g ). Importantly, like DA2 v-Src cells (Figure 5c ), WT FAK-GFP-expressing cells exhibited a maximal threefold increase in early tumor growth over days 10-15 (Figure 6g and data not shown). However, F925 FAK-reconstituted cells formed tumors equal in size to GFP controls whereas R454 FAK-expressing cells formed smaller tumors than GFP controls (Figure 6g ). These results support the conclusion that both FAK catalytic activity and Y925 phosphorylation are required for Src-stimulated tumor growth.
Analyses of FAKÀ/À v-Src GFP control, F925 FAK and R454 FAK tumors revealed a highly dense tumor mass with no specific staining with antibodies to VEGF or Tie-2 (Figure 7 ). In contrast, WT FAK tumors contained numerous sinusoids and exhibited strong VEGF staining around blood vessels (Figure 7) . A few Tie2-positive blood vessels were present in the WT FAK tumor interior, but most were located at the tumor periphery (Figure 7) . These results support the conclusion that FAK signaling controls angiogenic tumor growth downstream of Src.
Rescue of focal adhesion kinase-null tumor growth and angiogenic defects by CA-MEK1 and VEGF In addition to VEGF differences visualized by tumor section staining, FAK-increased VEGF expression was also detected by blotting lysates of cells grown in culture (Figure 8a ). Wild-type FAK increased VEGF-164 and VEGF-120 dimer isoform expression compared to R454 FAK, F925 FAK and GFP control FAKÀ/À v-Src cells ( Figure 8a) . As determined by ELISA of cell-conditioned media, there was >10-fold difference in VEGF expression between control GFP and WT FAK cells (Figure 8b (Figure 8b ) supporting the conclusion that elevated ERK/MAP kinase activation in the absence of FAK is sufficient to overcome defects in VEGF production, angiogenesis and tumor growth.
To test the importance of VEGF in promoting this angiogenic and tumor growth switch in cells lacking FAK, recombinant VEGF was added to GFP control FAKÀ/À v-Src cells after implantation on chicken CAMs. VEGF addition promoted a B3-fold increase in tumor mass compared to untreated GFP control cells with a mean tumor size slightly larger than untreated WT FAK reconstituted cells (Figure 8c ). Medial tumor sections of VEGF-treated FAKÀ/À v-Src cells stained for Tie-2 showed that VEGF addition promoted neovascularization whereas the untreated control tumors remained avascular (Figure 8d ). These studies show that VEGF is necessary and sufficient to override the requirement for FAK expression in promoting tumor growth. Importantly, as VEGF addition (100 ng/ml) did not affect FAKÀ/À v-Src fibroblast proliferation in cell culture (data not shown), increased VEGFinduced growth of cells as tumors is unlikely to occur through direct effects on FAKÀ/À v-Src fibroblasts. As knockdown of FAK expression in 4T1 breast carcinoma, PC3 prostate carcinoma, and NB8 neuroblastoma cells also resulted in reduced VEGF expression as determined by ELISA (Figure 8e ), our combined results establish that FAK signaling plays important roles promoting VEGF expression, angiogenesis and tumor progression. 
Discussion
Emerging evidence supports an important role for integrin-associated signals in the regulation of tumor growth. Whereas changes in FAK tyrosine phosphorylation have been implicated in b1-integrin-associated mammary tumor progression, mice or primary cells lacking b1 integrin or FAK are also susceptible to elevated apoptosis (Ilic et al., 1995; McLean et al., 2004; White et al., 2004; Li et al., 2005) . Thus, in these models, it is difficult to separate a basic role of FAK in promoting cell survival as opposed to a specific role for FAK in tumor progression.
Here, we have discovered that FAK expression, catalytic activity, and Y925 phosphorylation promote an ERK2-associated angiogenic switch enhancing tumor growth in vivo. The FAK-associated aggressive tumor phenotype was linked to enhanced VEGF expression and tumor neo-vascularization without differences in cell proliferation or anchorage-independent survival in cell culture. As studies have implicated FAK as a scaffolding protein functioning to recruit Src-family kinases, this is the first study to define a biological role for intrinsic FAK activity in promoting tumor growth (McLean et al., 2005; Mitra et al., 2005) . Additionally, although Y925 phosphorylation has been shown to promote Grb2 binding, previous studies using F925 FAK have not yielded definitive proof that this linkage facilitates MAPK activation possibly due to the competing presence of endogenous FAK (Schlaepfer and Hunter, 1997; Schlaepfer et al., 1998) . Here, we provide the first analyses of F925 FAK reconstituted FAK-null cells and show that Y925 phosphorylation is important in promoting ERK2 activity, VEGF expression, and tumor growth downstream of activated Src.
Our studies were performed using a combined dominant-negative strategy of FRNK expression in 4T1 murine breast carcinoma cells and complementary gain-of-function tumor growth assays in v-Src-transformed FAKÀ/À fibroblasts. Both 4T1 carcinoma (Heppner et al., 2000) and FAKÀ/À fibroblasts (Ilic et al., 1995) lack functional p53 and only under extreme overexpression conditions has FRNK been associated with cell apoptosis (Xu et al., 2000) . Importantly, no differences in cell proliferation in vitro or cell survival/ apoptosis in vivo were detected in the FRNK-or FAKnull-expressing tumors. In 4T1 cells, FAK activity is stimulated by fibronectin binding to integrins (Mitra et al., 2006) and thus, FRNK expression resulting in reduced FAK activity disrupts this linkage to integrins. FRNK S1034, which does not localize to sites of integrin clustering, did not inhibit FAK activity, was also stably expressed in 4T1 cells, and was effectively used as a control. FRNK expression resulted in the dephosphorylation of FAK at Y925, disruption of Grb2 binding to FAK, and the inhibition of ERK2 activity and VEGF expression. 4T1-FRNK cells formed tumors, but these were small and avascular compared to 4T1-FRNK S1034 controls.
FAKÀ/À fibroblasts exhibit motility but not proliferation defects in cell culture (Ilic et al., 1995) . v-Src is a potent oncogene that transforms FAKÀ/À cells and promotes cell motility in the absence of FAK (Hsia et al., 2003; Moissoglu and Gelman, 2003) . Although v-Src is a strong promoter of tumor growth and VEGF expression (Jiang et al., 1997) , we found that FAK expression is required for maximal v-Src-stimulated ERK2 activity and that FAK controls the v-Srcstimulated angiogenic switch. Notably, FAKÀ/À v-Src cells reconstituted with a catalytically inactive (R454) FAK or a Y925 phosphorylation site mutant (F925) FAK did not facilitate v-Src-stimulated ERK2 activation and formed avascular tumors similar to control FAKÀ/À v-Src cells. Enhanced VEGF expression, tumor growth and neo-vascularization were observed only in FAKÀ/À v-Src cells reconstituted with WT FAK. Together with the 4T1-FRNK results, these studies support the conclusion that FAK catalytic activity and Grb2 binding to FAK are required for FAK function in promoting tumor angiogenesis. Additionally, our results also provide a potential mechanistic explanation for the required role of FAK in promoting ErbB-2/ErbB-3 oncogenic transformation via enhanced activation of the MAPK pathway (Benlimame et al., 2005) .
In both 4T1-FRNK and FAKÀ/À v-Src cells, CA-MEK1 expression increased VEGF production and CA-MEK1 or recombinant VEGF addition also rescued the tumor neo-vascularization and growth defects of these cells. Importantly, recombinant VEGF addition did not alter cell proliferation in vitro. This is due to the fact that 4T1 cells express only neuropilin-1 and Flt-1 as VEGF receptors (Barr et al., 2005) and FAKÀ/À v-Src fibroblasts do not express Flk-1. The fact that the 4T1 and FAKÀ/À v-Src cells were not directly responsive to changes in VEGF and that 4T1 cells with active FAK could condition media to promote VEGF-dependent HUVEC proliferation, supports the conclusion that FAK promotes tumor angiogenesis in part through the regulation of VEGF expression.
Although we found that FAK signaling to ERK increased VEGF production under normal oxygen conditions, one of the major activators of tumorassociated VEGF expression is hypoxia within the growing tumor center (Pages and Pouyssegur, 2005) . Interestingly, hypoxia can enhance FAK tyrosine phosphorylation and promote Grb2 binding to FAK in cultured cardiac myocytes (Seko et al., 1999) . In a mouse model of hypoxia-induced retinal angiogenesis, FAK overexpression facilitated retinal neo-vascularization (Kornberg et al., 2004) . Additionally, FAK overexpression in vascular endothelial cells promoted angiogenesis in transgenic mice (Peng et al., 2004) and FAK expression is elevated in angiogenic blood vessels within astrocytic-associated tumor stroma compared to normal brain endothelial cells (Haskell et al., 2003) . Taken together, emerging evidence supports important roles for FAK in both tumor and endothelial cells during the induction of the angiogenic switch (Figure 9) .
Additionally, FAK expression within endothelial cells is required for developmental vasculogenesis and conditional endothelial cell-specific fak-null animals exhibit a late embryonic lethal phenotype (Shen et al., 2005) . Interestingly, reconstitution of FAK-null endothelial cells revealed that FAK catalytic activity was required to promote VEGF-stimulated motility (Shen et al., 2005) . This is a significant finding as previous studies have found that VEGF-mediated c-Src activation promoting FAK Y861 phosphorylation and FAK association with integrin avb5 as events important for endothelial cell motility (Eliceiri et al., 2002) (Figure 9 ). The fact that FAK catalytic activity is required for both the tumor-generating angiogenic stimulus and the endothelial cell motility response, suggests that the development of pharmacological inhibitors to FAK may function as potent anti-tumor growth and anti-angiogenic agents.
Materials and methods
Cells and antibodies MCF-7, MDA-MB-231, MDA-MB-468, MDA-MB-231, 4T1, and PC3 carcinoma cells were from ATCC, Manassas. Human umbilical vein endothelial cells were purchased from GlycoTech, Gaithersburg, MD, USA. NB8 human neuroblastoma cells were obtained from St Jude's Research Hospital, Memphis (Teitz et al., 2000) . Focal adhesion kinaseÀ/À v-Src and clonally derived FAK-reconstituted (DA2 v-Src) fibroblasts were used as described (Hsia et al., 2003) . Fibroblast and carcinoma cells were grown in DMEM supplemented with 10% FBS, HUVECs were grown in EGM, Fisher Scientific, Pittsburgh, PA, USA. NB8 cells were grown in RPMI with 10% FBS. Polyclonal rabbit anti-FAK 5592 (directed to FAK residues 853-1052), rabbit anti-FAK 5904 (directed to residues 8-27), rabbit anti-Grb2 5647 (directed to residues 195-217), monoclonal antibody (mAb) anti-HA (12CA5), and mAb anti-ERK2 (B3B9) antibodies were used for IPs or western blotting as described (Sieg et al., 1999) . Affinity-purified polyclonal antibodies were purchased from Biosource International, Camarillo, CA, USA (pERK1/ 2, pS298 MEK1, FAK pY397, FAK pY576, FAK pY577, FAK pY861 and FAK pY925), Santa Cruz Biotechnology, Santa Cruz, CA, USA (Tie-2), and Cell Signaling Technology, Danvers, MA, USA (p217/221 MEK1). MAbs were purchased from Upstate, Charlottesville, VA, USA (pTyr clone 4G10, pS10 Histone H3 clone 3H10 and v-Src clone EC10), Covance Research Products, Princeton, NJ, USA (GFP clone B34), SIGMA, St Louis, MO, USA (b-actin clone AC-74), BD Biosciences, San Diego, CA, USA (MEK1 clone 25), and Santa Cruz Biotechnology (VEGF, clone C-1). Anti-integrin avb3 (LM609) and anti-integrin avb5 (P1F6) were generated and purified as described (Friedlander et al., 1995) . VEGF and bFGF levels in cell-conditioned medium were quantified by Quantikine ELISA kits (R&D systems, Minneapolis, MN, USA). Short interfering RNA oligonucleotides were designed to nucleotides 394-415 of mouse FAK and nucleotides 1089-1107 of human FAK. A scrambled oligonucleotide 5 0 -aagucuccgaacgugucacguuu-3 0 was used as control.
Retroviral, lentiviral and adenoviral constructs N-terminal GFP-tagged R454 FAK, F925 FAK and FRNK S1034 fusions were prepared as described (Ilic et al., 1998) . GFP-FAK (4097 bp), GFP-FRNK (2077 bp) or GFP (776 bp) coding regions were excised from pEGFP-C1 by NheI and HincII digestion. DNA fragments were blunt-end cloned into the SnaBI site of the pBabe Puro retroviral vector.
Retroviruses were produced via transfection of 293-PhoenixEco-packaging cells as described (Sieg et al., 1999) . Target cells were infected for 24 h in retroviral-containing media with 5 mg/ ml polybrene, and after 72 h, cells were sorted by flow cytometry (FACS) for GFP expression using a FACS Vantage DiVa I, BD Biosciences. For FAKÀ/À v-Src cells, puromycin was used to select for v-Src expression and stable pooled populations of GFP-FAK-expressing cells were established by FACS. GFP-tagged FRNK and FRNK S1034 lentiviral constructs were prepared by BamHI excision from pBabe Puro and subcloned into pVIPER (Tschan et al., 2003) . DNA sequencing was used to confirm all cloning and mutagenesis steps. For lentiviral production, 10 mg of either FRNK construct were co-transfected with 6.5 mg CMVDR8.74 and 3.5 mg VSVG (Naldini et al., 1996) into 293T cells. After 48 h, the culture supernatants were spin concentrated using Apollo 150 kDa cutoff concentrators (CLP, San Diego, CA, USA) and used to infect 4T1 cells for 24 h. Cells were sorted for GFP expression until X90% of pooled cells expressed 10-100-fold higher GFP levels compared to auto-fluorescence of uninfected cells. Recombinant Ad for constitutively active human MEK1 (S217E, S221E) was purchased from Cell Biolabs Inc., San Diego, CA, USA and was used to infect 4T1 or FAKÀ/À v-Src cells at a multiplicity of infection of 50 plaque-forming units per cell. Protein lysates or egg innoculation of infected cells was carried out 48 h after virus addition.
Protein extraction, immunoprecipitation and in vitro kinase assays Protein lysates were prepared using lysis buffer containing 1% Triton X-100, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS). Target proteins were IP using 2.5 mg antibody addition and collected with protein A (Repligen, Waltham, MA, UK) or Protein G Plus (Invitrogen, Carlsbad, CA, USA) beads at 41C. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), antibody blotting, and sequential membrane re-probing was performed as described (Sieg et al., 1999) . Extracellular signal-regulated kinase (ERK)2 IVK was measured using myelin basic protein. For FAK IVK assays, FAK IPs were washed once in lysis buffer, once in lysis buffer without deoxycholate and SDS, twice in HNTG buffer (20 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (Hepes) pH 7.4, 150 mM NaCl, 0.1% Triton, and 10% glycerol), and once in kinase buffer (20 mM Hepes pH 7.4, 10% glycerol, 10 mM MgCl2, 10 mM MnCl2, 150 mM NaCl). Kinase assays were initiated by addition of 25 mCi of (g-32 P) ATP (6000 Ci/mmol; NEB) in a total volume of B30 ml, incubated for 15 min at 321C, and stopped by the addition of 2 Â Lamelli sample buffer. For all IVK assays, proteins were separated by SDS-PAGE, transferred to polyvinylidine difluoride membranes (Millipore, Billerica, MA, USA), labeled proteins were quantified by a PhosphorImager (GE Healthcare Life Sciences, Piscataway, NJ, USA), and equal recovery of the immuno-isolated kinase was verified by blotting.
Heparin sepharose purification
In all, 3 Â 10 6 4T1 cells were plated in 10 cm dishes in growth media. After 3 h, cells were washed with PBS and media replaced (DMEM þ 0.5% FBS). After 48 h, conditioned media (40 ml) was pooled, 0.6 ml of pre-swollen heparin sepharose beads (CL-6B, GE Healthcare Life Sciences) was added and incubated for 3 h at 41C. Of unconditioned starvation medium, 40 ml was used as a negative control. Heparin sepharose beads were collected in poly-prep chromatography columns (Biorad Laboratories, Hercules), washed with 10 ml equilibration buffer (10 mM Tris-HCl pH 7.5), and then eluted with 10 ml equilibration buffer containing 0.8 M NaCl. Eluates were dialyzed overnight at 41C, concentrated to 1 ml by spin centrifugation (10 kDa cutoff Apollo, CLP), and used within 24 h.
Cell proliferation and apotosis assays
Anchorage-dependent cell proliferation was evaluated by plating 10 4 cells in twelve 35 mm wells in growth media or low serum (0.5% FBS) conditions. Focal adhesion kinaseÀ/À v-Src, DA2 v-Src and GFP-FAK reconstituted cells were plated into uncoated wells whereas 4T1 cells were plated on 10 mg/ml collagen type I-coated wells. Two wells of cells were trypsinized daily and counted. Anchorage-independent assays were performed similarly using poly-hydroxyethyl methacrylate (HEMA)-coated ultra-low attachment plates (Costar, Fisher Scientific). In all, 5 Â 10 4 cells were plated per well and every 24 h, cell spheroids were collected from two individual wells, trypsinized and counted. All growth experiments were repeated at least twice.
For apoptosis assay, 2 Â 10 5 cells were plated per 35 mm well on poly-HEMA plates and allowed to grow for 48, 72 or 96 h. Spheroids were collected, single-cell suspension was prepared using enzyme-free dissociation buffer (Invitrogen Life Technologies), and subjected to Annexin V/7-amino-actinomycin D staining using a kit, BD Biosciences. Soft agar assays were performed as described (Hauck et al., 2002) . For HUVEC proliferation assays, 3 Â 10 5 cells were plated onto 10 mg/ml collagen type I-coated glass coverslips for 3 h in EGM, washed with PBS, and placed into starvation medium (MCDB 131 medium (Invitrogen) containing 0.2% FBS, 1% BSA, 0.1 mM sodium pyruvate, 0.01 mM MEM non-essential amino acids, 1 Â glutMAX). After 16 h, media was replaced either with EGM (positive control), starvation medium (negative control), or 2 ml DMEM (containing 5% FBS) with 1 ml 4T1-conditioned medium in the presence of BrdU. VEGF receptor 2 kinase inhibitor (SU5416, Calbiochem, San Diego, CA, USA) or human recombinant VEGF (PeproTech, Rocky Hill, NJ, USA) were added with the BrdU as indicated. After 48 h, cells were stained according to manufacturer's instructions (BrdU Labeling and Detection Kit I, Roche Dignostics, Indianapolis, IN, USA), and photographed at Â 20 magnification (Olympus objectives, Temecula, CA, USA) using an inverted microscope (IX51, Olympus). Duplicate coverslips were processed in parallel for TUNEL staining as recommended (In Situ Cell Death Detection Kit, TMR Red; Roche Diagnostics). Values were determined in duplicate by counting four Â 20 fields of BrdU or TUNEL-positive cells (>200 cells) divided by total cell number.
Mouse and chorioallantoic membrane tumor growth assays Animal experimentation was undertaken according to protocols approved by the Institutional Animal Care and Use Committee at Scripps. Growing cells from semi-confluent dishes were trypsinized, washed with PBS, resuspended in DMEM (without FBS), and counted. In all, 10 6 cells were injected subcutaneously on the backs of anaesthetized Balb/c or nude mice (Athymic WeHi, bred at Immunology Vivarium, TSRI, La Jolla, USA). Tumors were measured daily using vernier calipers and tumor volumes were computed using the formula (volume ¼ length Â (width 2 )/2, where the larger of the two dimensions was considered tumor length). Tumors were allowed to grow for the times indicated and experiments were terminated prior to signs of animal distress. Chorioallantoic membrane assays were performed as described (Storgard et al., 2004) . Briefly, an egg window was created and 10 6 -10 7 cells (as indicated) from a centrifuged cell pellet (B50 ml) were placed on the CAM of a 7-day-old fertilized chicken egg. Eggs were maintained in a humidified incubator (Lyon electric company, Chula Vista, CA, USA) at 381C for 7 days, after which time the tumors were excised and weighed.
Egg and mouse injections 7-day old chicken eggs were illuminated to identify regions containing blood vessels and separate windows were made for the addition of tumor cells (top) and injection of antibodies or lectins (side). On day 10, the shell in the side window region was removed with the aid of paraffin oil and B50 ml of 1 mg/ml FITC-lectin (Lens culinaris agglutinin, Vector Labs, Burlingame, CA, USA) or 25 ml of 125 mg/ml blocking antibodies (LM609 or P1F6) were injected intravenously. Only the eggs that showed visible clearing in the veins upon injection were scored. For the lectin studies, eggs were incubated for 15 min and then euthanized by placing on ice. Tumors were excised, normalized for total protein content using a Bradford assay, and FITC content was measured using a fluorimeter. For antibody blocking studies, tumors were excised 3-4 days after antibody injection. Exogenous VEGF addition (Peprotech, murine VEGF-164) was added to the tumor implantation site (10 ml of 1 ng/ml) every other day. For mouse in situ labeling of endothelial cells, 20 ml of 1 mg/ml FITC-conjugated isolectin b4 (Griffonia simplicifolia Lectin I, Vector Labs) was injected into tail veins of mice bearing 3-week old tumors (final concentration B10-15 mg/ml in circulation). After 30 min, mice were euthanized by metofane overdose and the tumors were surgically removed.
Histology, immunostaining, and GFP fluorescence All tumors were mounted in standard or biopsy-sized cryomolds using OCT (Electron Microscopy Sciences, Hatfield, PA, USA) and immersed into 2-methyl butane (Electron Microscopy Sciences) on dry ice. Frozen tumors were stored at À701C. Thin sections (7 mm) were obtained using a cryostat (Leica CM3050S) and mounted onto glass slides. FITC-lectin staining was observed on unfixed tumor sections. For antibody immunostaining, tumor sections were fixed with acetone for 15 min at À201C. Polyclonal rabbit Tie-2 (1:200 dilution) Ab reactivity was detected using RTU. Vectastain Universal Quick and diaminobenzidine (DAB) Substrate Kits as recommended by the manufacturer (Vector Labs). Monoclonal anti-VEGF (1:100 dilution) reactivity was detected using the mouse on mouse (MOM) immunodetection kit (Vector Labs). Diaminobenzidine color development was carried out in the absence of nickel and cell nuclei were counter-stained blue using Mayer's hematoxylin solution (SIGMA). Photographs were taken at Â 20 magnification (Nikon objectives, NA ¼ 0.4) using an inverted microscope (NIKON, Lake Forest, CA, USA). Tumor GFP staining was visualized by lightly fixing tumor sections in 1% paraformaldehyde for 15 min and counter-staining with 10 mg/ml Hoechst 33342. Photographs were taken at Â 20 magnification (Olympus UPLFL objective, NA ¼ 0.5) using a monochrome CCD camera (ORCA ER, Hamamatsu, Melville, NY, USA) and an inverted microscope (IX51, Olympus). Corresponding fields were captured in the blue and wide ultraviolet wavelengths, pseudo-colored, and merged to generate dual-stained images.
Reverse transcriptase-polymerase chain reaction RNA was prepared using TriZOL (Invitrogen Life Technologies). Of total RNA, (5 mg) was used as a template for reverse transcription (Superscript First Strand synthesis kit, Invitrogen). Semiquantitative RT-PCR (38 cycles) was performed with VEGF-specific primer pairs (forward 5 0 -gag atg agc ttc cta cag cac-3 0 ; reverse 5 0 -tca ccg cct cgg ctt gtc ac-3 0 ) and the co-amplification of b-actin (added for the last 18 PCR cycles) was used as an internal standard for all reactions. Cycling conditions were 951C for 30 s, 551C for 40 s and 721C for 1 min (PTC-100, MJ Research).
Statistical analyses
Student's t-test was used for pairwise comparisons and oneway analysis of variance was used groupwise comparisons.
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